tiprankstipranks
TipRanksStock Market NewsIDYA NewsAnalysts Offer Insights on Healthcare Companies: DENTSPLY SIRONA (XRAY), Turning Point Therapeutics (TPTX) and IDEAYA Biosciences (IDYA)
Blurbs

Analysts Offer Insights on Healthcare Companies: DENTSPLY SIRONA (XRAY), Turning Point Therapeutics (TPTX) and IDEAYA Biosciences (IDYA)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on DENTSPLY SIRONA (XRAYResearch Report), Turning Point Therapeutics (TPTXResearch Report) and IDEAYA Biosciences (IDYAResearch Report).

DENTSPLY SIRONA (XRAY)

In a report released yesterday, Jonathan Block from Stifel Nicolaus maintained a Hold rating on DENTSPLY SIRONA, with a price target of $40.00. The company’s shares closed last Thursday at $37.85, close to its 52-week low of $35.00.

According to TipRanks.com, Block is a 5-star analyst with an average return of 14.0% and a 57.0% success rate. Block covers the Healthcare sector, focusing on stocks such as Idexx Laboratories, Envista Holdings, and SmileDirectClub.

Currently, the analyst consensus on DENTSPLY SIRONA is a Moderate Buy with an average price target of $47.62, which is a 27.3% upside from current levels. In a report issued on May 10, Piper Sandler also maintained a Hold rating on the stock with a $41.00 price target.

See the top stocks recommended by analysts >>

Turning Point Therapeutics (TPTX)

In a report issued on May 11, Bradley Canino from Stifel Nicolaus maintained a Hold rating on Turning Point Therapeutics, with a price target of $38.00. The company’s shares closed last Thursday at $29.33, close to its 52-week low of $23.77.

According to TipRanks.com, Canino is ranked 0 out of 5 stars with an average return of -49.6% and a 3.0% success rate. Canino covers the Healthcare sector, focusing on stocks such as Black Diamond Therapeutics, Zentalis Pharmaceuticals, and Arvinas Holding Company.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Turning Point Therapeutics with a $108.75 average price target, implying a 329.8% upside from current levels. In a report issued on April 28, JMP Securities also maintained a Hold rating on the stock.

IDEAYA Biosciences (IDYA)

In a report issued on May 11, Benjamin Burnett from Stifel Nicolaus maintained a Buy rating on IDEAYA Biosciences, with a price target of $16.00. The company’s shares closed last Thursday at $10.12, close to its 52-week low of $8.14.

According to TipRanks.com, Burnett is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -24.5% and a 14.3% success rate. Burnett covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Iovance Biotherapeutics, and Crispr Therapeutics AG.

Currently, the analyst consensus on IDEAYA Biosciences is a Strong Buy with an average price target of $25.67.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on XRAY:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More